一项评估 CS0159 在 NASH 受试者中的安全性、耐受性、药代动力学和疗效的研究
一项评估 CS0159 治疗非酒精性脂肪性肝炎 (NASH) 患者的安全性、耐受性、药代动力学和疗效的 II 期、随机、双盲、安慰剂对照多中心研究
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
研究概览
详细说明
This will be a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PKs, and efficacy of CS0159 in the treatment of patients with NASH over 12 weeks.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Gardena、California、美国、90247-3586
- National Research Institute - Gardena
-
Huntington Park、California、美国、90255-2959
- Velocity Clinical Research, Huntington Park
-
Panorama City、California、美国、91402-3022
- Velocity Clinical Research - Panorama City
-
Santa Ana、California、美国、92704
- Velocity Clinical Research - Santa Ana
-
-
Florida
-
Lady Lake、Florida、美国、32159
- Ocala GI Research
-
Lakewood、Florida、美国、34211-4930
- Florida Research Institute
-
Miami、Florida、美国、33014-5602
- San Marcus Research Clinic, Inc - Miami
-
Miami Lakes、Florida、美国、33016-1518
- Floridian Clinical Research, LLC - Miami Lakes
-
Ocala、Florida、美国、34471
- Gastroenterology Associates of Ocala
-
-
Georgia
-
College Park、Georgia、美国、30349
- Oracle Clinical Research
-
-
Louisiana
-
Marrero、Louisiana、美国、70072
- Metropolitan Gastroenterology Associates - Westbank Office and Endoscopy
-
-
Maryland
-
Greenbelt、Maryland、美国、20770-6702
- Raja M. Din MD, PLLC - Gastroenterology & Hepatology
-
-
North Carolina
-
Morehead City、North Carolina、美国、28557
- Lucas Research
-
-
Texas
-
Austin、Texas、美国、78757-7571
- Texas Liver Institute (TLI) - Austin
-
Houston、Texas、美国、77099-4307
- Pioneer Research Solutions Inc - Houston - Stancliff Rd
-
San Antonio、Texas、美国、78229
- Clinical Trials of Texas, LLC
-
San Antonio、Texas、美国、78215
- The Texas Liver Institute, Inc.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients who meet the diagnosis of NASH.
- Evidence of metabolic syndrome, except for those patients with biopsy-proven NASH.
- Body mass index (BMI) >25 kg/m2, NOTE: for Asian-Americans BMI >23 kg/m2.
- Stable use of other antidiabetic, weight loss, or lipid-modifying medications for at least 12 weeks prior to randomization.
Exclusion Criteria:
-
Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer.
-
Previous exposure to farnesoid X receptor (FXR) agonists 3 months prior to the first dosing.
-
Current or within 6 months of screening use of drugs associated with steatosis, including but not limited to eg, methotrexate, amiodarone, high-dose estrogen, tamoxifen, long term systemic steroids, anabolic steroids, valproic acid.
-
Prothrombin time international normalized ratio >1.3, unless due to therapeutic anticoagulation.
-
Total bilirubin >upper limit of normal (ULN; except for patients with Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count).
Platelet count <140 000/mm³, absolute neutrophil count <1500 cells/mm3, or total
-
white blood cells <3000 cells/mm3.
-
Alanine aminotransferase and aspartate aminotransferase (AST) >5 × ULN, or alkaline phosphatase (ALP) >1.5 × ULN.
-
Weight changes >10% in 6 months prior to screening, or weight changes >5% from the screening MRI-PDFF to randomization or from the time of the diagnostic liver biopsy to randomization, whichever is longer.
-
Poorly controlled hypertension (systolic >160 mm Hg, or diastolic blood pressure >100 mm Hg - mean of 3 measurements).
-
Uncontrolled diabetes mellitus (hemoglobin A1c >10.0% during screening).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:1.4mg CS0159
One tablet daily for 12 weeks |
Oral QD
其他名称:
|
|
实验性的:2mg CS0159
One tablet daily for 12 weeks |
Oral QD
其他名称:
|
|
安慰剂比较:PLACEBO
One tablet daily for 12 weeks |
Oral QD
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
MRI-PDFF
大体时间:Week 12
|
To assess the percentage changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12 |
Week 12
|
|
Adverse Events
大体时间:Week 12
|
To evaluate the safety and tolerability of CS0159 in patients with NASH treated over 12 weeks |
Week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cmax
大体时间:Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
maximum concentration (Cmax) |
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
|
Tmax
大体时间:Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
time to maximum plasma concentration (tmax) |
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
|
t1/2
大体时间:Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
half-life (t1/2) |
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
|
AR(AUC)
大体时间:Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
accumulation ratio of area under the concentration-time curve (AUC) in plasma from baseline to day42 |
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
|
Pharmacodynamics (PD)-Fibroblast Growth Factor 19
大体时间:Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
Plasma concentrations and PD parameters of the biomarkers of FXR target engagement fibroblast growth factor 19 from baseline to day42 |
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
|
Pharmacodynamics (PD)-C4
大体时间:Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
Plasma concentrations and PD parameters of the biomarkers of FXR target engagement 7-alpha-Hydroxy-4-cholesten-3-one(C4) from baseline to day42 |
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
|
合作者和调查者
调查人员
- 研究主任:Rong Deng、Cascade Pharmaceuticals, Inc
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.